Dyne Therapeutics, Inc.
DYNHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeDyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. At a $2.85B market cap, Dyne Therapeutics, Inc. ranks as a mid-cap company within healthcare. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Market Cap
$2.85B
Beta
1.08
P/E (TTM)
—
P/E (Fwd)
-5.78
EPS (TTM)
$-3.15
EPS (Fwd)
$-2.98
ROE
-58.9%
ROA
-32.7%
Cash
$972.2M
Total Debt
$168.7M
Free CF
-$292.3M
52W Change
28.6%
Annual Financials
Cash vs Debt
With $972.2M in cash and $168.7M in debt, DYN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$292.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -58.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DYN.